A voltammetric immunoassay for the carcinoembryonic antigen using silver(I)-terephthalate metal-organic frameworks containing gold nanoparticles as a signal probe

Liu, Jianbo; Shang, Yonghui; Zhu, Qi; Zhang, Xinxue; Zheng, Jianbin

doi:10.1007/s00604-019-3638-8

Cited by 27 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors emphasized that the sensor could be used for the POCT of CEA from human serum. Aside from MNP-carbon material-based composites, metal oxide NPs, core shell MNPs, quantum dot NPs, graphene, MOF, etc., have extensively been studied as the electrode probes for fabricating both labeled or label-free sandwich immunosensing arrays for the ultrasensitive detection of CEA for early-stage cancer diagnoses [196,202,209,[211][212][213][214][215][216].…”

Section: Mnps In Cancer Biomarker Detectionmentioning

confidence: 99%

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

et al. 2020

View full text Add to dashboard Cite

With the rise in public health awareness, research on point-of-care testing (POCT) has significantly advanced. Electrochemical biosensors (ECBs) are one of the most promising candidates for the future of POCT due to their quick and accurate response, ease of operation, and cost effectiveness. This review focuses on the use of metal nanoparticles (MNPs) for fabricating ECBs that has a potential to be used for POCT. The field has expanded remarkably from its initial enzymatic and immunosensor-based setups. This review provides a concise categorization of the ECBs to allow for a better understanding of the development process. The influence of structural aspects of MNPs in biocompatibility and effective sensor design has been explored. The advances in MNP-based ECBs for the detection of some of the most prominent cancer biomarkers (carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), Herceptin-2 (HER2), etc.) and small biomolecules (glucose, dopamine, hydrogen peroxide, etc.) have been discussed in detail. Additionally, the novel coronavirus (2019-nCoV) ECBs have been briefly discussed. Beyond that, the limitations and challenges that ECBs face in clinical applications are examined and possible pathways for overcoming these limitations are discussed.

show abstract

Section: Mnps In Cancer Biomarker Detectionmentioning

confidence: 99%

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

et al. 2020

View full text Add to dashboard Cite

show abstract

“…24 The broad band centered around 3000 cm À1 in the TP spectrum disappears in ATP, indicating the formation of the O-Ag bond. 25 The O-Ag bond is further confirmed from the characteristic weak peak observed at 504 cm À1 , while the peak at 740 cm À1 corresponds to COO-bending.…”

Section: Resultsmentioning

confidence: 81%

A long-lived photoluminescent silver nanocluster-infused silver terephthalate metal organic framework with antibacterial and biofilm inhibition activity: a high functional resource

George,

Prathapan,

Manoj

et al. 2023

J. Mater. Chem. C

View full text Add to dashboard Cite

show abstract

“…Therefore, the fluorescence intensity of Ag-MOFs in the lysosome gradually increased with time (0–48 h), indicating that Ag-MOF can locate the drug through its own fluorescence characteristics. It has been reported that the synthesized Ag-MOFs were composed of different organic ligands. − However, none of the above Ag-MOFs reported fluorescence characteristics. Hence, we reported for the first time that the constructed Ag-MOFs have fluorescence characteristics; second, PFK15 in Ag-MOFs present an acid-response release, which was especially suitable for tumor weak acidic environment.…”

Section: Discussionmentioning

confidence: 99%

Smart Biomimetic Nanocomposites Mediate Mitochondrial Outcome through Aerobic Glycolysis Reprogramming: A Promising Treatment for Lymphoma

Zhao

et al. 2020

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Toxicity and drug resistance caused by chemotherapeutic drugs have become bottlenecks in treating tumors. The delivery of anticancer drugs based on nanocarriers is regarded as an ideal way to solve the aforementioned problems. In this study, a new antilymphoma nanodrug CD20 aptamer-RBCm@Ag-MOFs/PFK15 (A-RAMP) is designed and constructed, and it consists of two parts: (1) metal–organic frameworks Ag-MOFs (AM) loaded with tumor aerobic glycolysis inhibitor PFK15 (P), forming a core part (AMP); (2) targeted molecule CD20 aptamer (A) is inserted into the red blood cell membrane (RBCm) to form the shell part (A-R). A-RAMP under the guidance of CD20 aptamer actively targets B-cell lymphoma both in vitro and in vivo. As a result, A-RAMP not only significantly inhibits the effect on tumor growth but also shows no obvious side effects on the treated nude mice, indicating that A-RAMP can accurately target tumor cells, reprogram aerobic glycolysis, and exert synergistic antitumor effect by Ag+ and PFK 15. Furthermore, the antitumor mechanism of A-RAMP in vivo by apoptotic pathway and targeting metabonomics are explored. These results suggest that A-RAMP has a promising application prospect as an smart, safe, effective, and synergistic antilymphoma agent.

show abstract

A voltammetric immunoassay for the carcinoembryonic antigen using silver(I)-terephthalate metal-organic frameworks containing gold nanoparticles as a signal probe

Cited by 27 publications

References 29 publications

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

A long-lived photoluminescent silver nanocluster-infused silver terephthalate metal organic framework with antibacterial and biofilm inhibition activity: a high functional resource

Smart Biomimetic Nanocomposites Mediate Mitochondrial Outcome through Aerobic Glycolysis Reprogramming: A Promising Treatment for Lymphoma

Contact Info

Product

Resources

About